Company history

Kirin’s origins are foreign. In 1869 the American William Copeland built Japan’s first beer brewery, the Spring Valley Brewery, on the Yamate bluff in Yokohama, supplying the foreign settlements of Yokohama and Nagasaki and exporting to Shanghai and Saigon for about fifteen years. In 1885 prominent foreign residents and Japanese business leaders founded the Japan Brewery Company on the Spring Valley site and built the country’s first modern brewery; its beer, named “Kirin Beer,” went on sale in 1888. Made with German brewing technique and good imported malt, it stood out for quality and sold nationwide at a premium from the start — the quality-first legacy that a foreign-run brewery handed to the later Kirin.

In 1907 men from Mitsubishi, Meiji-ya and Nippon Yusen established Kirin Brewery Company, taking over Japan Brewery’s assets and engineers and moving management into Japanese hands. It was built on a division of labour — Kirin manufactured, Meiji-ya distributed, Mitsubishi supplied the capital — which spared it from being swallowed by the era’s giant mergers. Through the Taisho boom, wartime demand and Southeast Asian exports lifted the whole industry; Kirin added the Kanzaki (later Amagasaki) plant in 1918, a Sendai plant in 1923, and a new Yokohama plant at Tsurumi in 1926 after the Great Kanto Earthquake destroyed the Yamate works. In 1927 it dissolved Meiji-ya’s sole-agency arrangement, absorbed its beer-sales division and set up its own sales department — inheriting a foreign legacy and making it independent under Japanese capital and engineers, the backbone of Kirin’s later self-reliance.

The decisive break came in 1949: the anti-monopoly deconcentration law split Dai-Nippon Beer — which had held more than 70% of the prewar market — into Nippon Beer (later Sapporo) and Asahi. Kirin, which escaped the breakup, revived its Meiji-era Kirin trademark and faced the two new rivals with steadily rising demand. Before the war, on-premise sales had taken 70% of the market and Kirin could reach only households; afterwards the democratization of beer and rising incomes flipped the ratio toward home consumption — exactly the segment Kirin led — and that reversal, together with the structural advantage of having avoided the split, propelled its share.

On the supply side Kirin expanded hard, opening a Tokyo plant in 1953 ahead of rivals and pouring $255.6M (¥92bn) into capacity between 1950 and 1968 — a 24-fold rise in shipments against the industry’s 14-fold. Its market share, just 25% in 1949, reached about 50% from 1966 and, in December 1972, topped 60.1%. The specialty-dealer network passed 760 outlets, and by the late 1960s Kirin was the world’s second-largest brewer after Anheuser-Busch.

But a share above half brought its own ceiling. Antitrust scrutiny narrowed the room to grow by volume, and in 1975 Kirin drew up its “Showa 50 Structural Plan,” turning toward stable growth and diversification into soft drinks and food. The same instinct to defend a dominant share — holding sales back rather than pressing them — began to harden into an organizational conservatism that would later show up as its slow answer to Super Dry.

Asahi’s Super Dry, launched in 1987, changed what drinkers chose, and Kirin’s share slid. Management first read it as a passing fad and could not bring itself to remake the taste of its flagship Lager: for a company with 60% of the market, changing the taste risked alienating the very customers it had, so “not changing” looked rational. Share fell to 48.5% in 1989 — below half for the first time in 24 years — and Kirin answered in March 1990 with Ichiban Shibori, brewed only from first-press wort at a cost it absorbed rather than passed on; the hit steadied share at 49.3% that year. Under president Sato Yasuhiro it entered happoshu with Tanrei in February 1998, and closed the Tokyo and Hiroshima plants in August 1998 and Kyoto in August 1999, with about half of the 550 staff at the three taking early retirement. Even so, in 2001 Kirin ceded the No. 1 beer/happoshu share to Asahi — ending 48 straight years at the top — and out of that reckoning came the resolve to break its dependence on a single category.

The answer had, in fact, been seeded years earlier and off to one side. In 1982 Kirin decided to turn the fermentation and culturing technology it had built brewing beer toward bio-pharmaceuticals, setting up a drug-research lab. It launched the EPO drug Espo in April 1990; by the late 1990s Espo and the white-cell drug Gran together sold about $307.4M (¥35bn) a year, and its US venture Kirin-Amgen was earning royalty income. The stable cash flow of beer underwrote the long research without demanding quick returns; in 2008 Kirin bought Kyowa Hakko Kogyo, formed Kyowa Kirin, and built a three-business portfolio of beer, beverages and pharmaceuticals — president Kato Kazuyasu calling pharma “the third pillar after alcohol and beverages.” The same circulation of core technology into adjacent fields would later carry into health science.

The push for scale ran first through Oceania, then through a merger that never happened. In November 2007 Kirin bought Australia’s leading dairy and beverage group, National Foods, from San Miguel for $2.5B (¥298bn) — “the largest in Kirin’s history,” said president Kato Kazuyasu — and in August 2008 agreed to add the No. 2, Dairy Farmers, for about $812.9M (¥84bn), lifting its milk share from 37% to 62.5% on roughly $3.7B (¥380bn) of total investment. In July 2009 Kirin and Suntory confirmed merger talks that would have joined companies with combined 2008 sales of about $36.8B (¥3.8tn). The talks collapsed in February 2010: Kirin offered an exchange ratio of 1 to 0.5 and moved to 0.75, Suntory held out for 0.6 or more, and with the founding family’s holding company owning about 89.3% of Suntory, Kirin concluded the two sides did not share a view of how independent and transparent a listed company must be.

In 2011, the year after the talks collapsed, Kirin Holdings bought Brazil’s second-largest brewer, Schincariol, for about $3.8B (¥304bn), chasing a market with a growing population and roughly 10% annual consumption growth. But almost at once it was pulled into a shareholder dispute among the founding family, and Brazilian price competition and a weak real compounded the problem; the internal family conflict that due diligence had missed hollowed out the returns. For the year ended December 2015 Kirin booked a roughly $908.9M (¥110bn) impairment on the Brazilian business and fell to a $390.8M (¥47bn) net loss — its first since listing — a hard lesson that entering a growth market does not by itself create value. In February 2017 it sold Brazil Kirin to Heineken’s Bavaria for $686.5M (¥77bn), leaving after about six years; consolidated net profit recovered to $1.1B (¥118bn) in 2016 and $1.1B (¥129bn) in 2017. Out of it came a shift from pursuing scale to pursuing quality: a discipline of selecting and concentrating overseas businesses, and of not postponing the decision to withdraw.

With the overseas expansion reined in — Kirin agreed in November 2020 to sell its Australian dairy-drinks arm for about $383M (¥41bn), sold its China soft-drink holding for about $875.4M (¥115bn) in February 2022 and exited Myanmar the same year — the company leaned on the stable earnings of domestic beer and beverages while pushing toward the higher-value fields of pharmaceuticals and health science. In March 2020 shareholders rejected all four proposals from the UK manager Independent Franchise Partners, which held about 2% of Kirin and wanted the pharma and health-science businesses and the Fancl stake sold and up to $5.6B (¥600bn) of stock bought back; the buyback motion drew 8.40% support. In June 2024 it launched a tender offer to take Fancl fully private — carried through in September after three extensions and a raised price, and completed in March 2025 — five years after a 2019 capital alliance, judging that a partial stake could never fully integrate the research and sales channels it wanted; the aim was to fuse Kirin’s fermentation and bio technology with Fancl’s consumer reach and make health science a pillar of growth. That same year leadership moved to a two-headed structure under Isozaki Yoshinori as chairman and CEO and Minakata Takeshi as president and COO, and Kirin began, in reverse, to tidy the sprawl its acquisitions had created — selling out of overseas beer and even the amino-acids business of Kyowa Hakko Bio — declaring the structural reform done and the company moved into a “growth-realization stage.” A brewer redefining its very business domain around fermentation, carrying the technology of its core into new fields, is a growth path bound up with a company culture that runs back to before the war.